PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 128 filers reported holding PUMA BIOTECHNOLOGY INC in Q3 2020. The put-call ratio across all filers is 1.91 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $52,000 | -68.7% | 5,004 | -73.7% | 0.02% | -54.5% |
| Q4 2019 | $166,000 | +403.0% | 19,009 | +511.4% | 0.03% | +266.7% |
| Q3 2019 | $33,000 | -86.9% | 3,109 | -84.3% | 0.01% | -87.7% |
| Q2 2019 | $252,000 | +950.0% | 19,845 | +3207.5% | 0.07% | +2333.3% |
| Q1 2019 | $24,000 | -46.7% | 600 | -71.9% | 0.00% | -80.0% |
| Q4 2018 | $45,000 | +400.0% | 2,139 | +969.5% | 0.02% | +650.0% |
| Q3 2018 | $9,000 | -93.6% | 200 | -92.0% | 0.00% | -93.8% |
| Q2 2018 | $141,000 | +2250.0% | 2,500 | +1150.0% | 0.03% | +3100.0% |
| Q4 2016 | $6,000 | -99.3% | 200 | -97.2% | 0.00% | -99.1% |
| Q2 2015 | $824,000 | +24.7% | 7,057 | +152.0% | 0.11% | -8.3% |
| Q1 2015 | $661,000 | +20.4% | 2,800 | -3.4% | 0.12% | -35.5% |
| Q4 2014 | $549,000 | – | 2,900 | – | 0.19% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Athyrium Capital Management, LP | 1,792,114 | $4,713,260 | 4.15% |
| Eversept Partners, LP | 1,681,149 | $4,421,422 | 0.37% |
| Camber Capital Management LP | 4,235,000 | $11,138 | 0.37% |
| Kynam Capital Management, LP | 473,975 | $1,246,554 | 0.20% |
| GLOBEFLEX CAPITAL L P | 538,559 | $1,416,410 | 0.17% |
| Affinity Asset Advisors, LLC | 202,349 | $532,178 | 0.15% |
| GSA CAPITAL PARTNERS LLP | 279,629 | $735 | 0.06% |
| RICE HALL JAMES & ASSOCIATES, LLC | 363,666 | $956,442 | 0.06% |
| Patriot Financial Group Insurance Agency, LLC | 67,000 | $176,210 | 0.04% |
| ACADIAN ASSET MANAGEMENT LLC | 1,858,000 | $4,884 | 0.02% |